Table 3.
Pt | Age | Size mm | Histology | Bilateral | Multifocal | ETE | LN Mets |
Dis
Mets |
---|---|---|---|---|---|---|---|---|
7 | < 45 | 9 | PTMC | – | – | – | + | – |
1 | < 45 | 8 | PTMCvF | – | + | + | + | – |
8 | ≥ 45 | 6 | PTMC | – | – | – | + | – |
3 | ≥ 45 | 5 | PTMC | – | + | + | + | – |
2 | ≥ 45 | 3 | PTMCvS | + | + | – | + | – |
5 | < 45 | 3 | PTMC | – | + | – | + | – |
6 | ≥ 45 | 3 | PTMCvF | + | + | – | + | + |
4 | ≥ 45 | 2.5 | PTMCvS | – | + | – | + | – |
9 | ≥ 45 | 2 | PMTCvF | – | – | – | + | – |
Pt patient, Bilateral bilaterality, Multifocal multifocality, ETE extra-thyroidal extension, LN Mets lymph node metastasis, Dis Mets distant metastasis, PTMC papillary thyroid microcarcinoma, vF variant follicular, vS variant sclerosing
+, present; -, absent
Bold values, LN metastasis in absence of any other high risk features